The Role of Ki-67 and ctDNA as Prognostic or Predictive Markers in Breast Cancer
Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.
Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
All patients with a response to TAR-200 did not have progression to muscle-invasive bladder cancer or metastatic disease in the SunRISe-1 trial.
Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.
Treatment with cretostimogene grenadenorepvec appears tolerable among patients with high-risk BCG–unresponsive NMIBC in the phase 3 BOND-003 trial.
Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.
Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.